Literature DB >> 17160995

Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.

Bassem T Chaar, Paul J Petruska.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17160995     DOI: 10.1002/ajh.20843

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

Review 1.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

2.  Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.

Authors:  H Coelho; M Badior; T Melo
Journal:  Case Rep Hematol       Date:  2017-07-27

3.  B-cell Prolymphocytic Leukemia: Case Report and Challenges on a Diagnostic and Therapeutic Forefront.

Authors:  Bikramjit S Bindra; Harpreet Kaur; Shellsea Portillo; Oluwadunni Emiloju; Katherine Garcia de de Jesus
Journal:  Cureus       Date:  2019-09-11

4.  Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.

Authors:  Maria Tariq Siddiqui; Allyson Price; Alessandra Ferrajoli; Gautam Borthakur
Journal:  Leuk Res Rep       Date:  2021-08-30

5.  A 80-Year-Old Woman with B-Cell Prolymphocytic Leukemia.

Authors:  Alparslan Merdin; Jale Yıldız; Sinan Dal Mehmet; Merih Kızıl Çakar; Hikmetullah Batgi; Emre Tekgündüz; Aykut Onursever; Fevzi Altuntaş
Journal:  Hematol Rep       Date:  2017-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.